1. Home
  2. ACRS vs TSE Comparison

ACRS vs TSE Comparison

Compare ACRS & TSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRS
  • TSE
  • Stock Information
  • Founded
  • ACRS 2012
  • TSE 2010
  • Country
  • ACRS United States
  • TSE United States
  • Employees
  • ACRS N/A
  • TSE N/A
  • Industry
  • ACRS Biotechnology: Pharmaceutical Preparations
  • TSE Major Chemicals
  • Sector
  • ACRS Health Care
  • TSE Industrials
  • Exchange
  • ACRS Nasdaq
  • TSE Nasdaq
  • Market Cap
  • ACRS 127.6M
  • TSE 151.9M
  • IPO Year
  • ACRS 2015
  • TSE 2014
  • Fundamental
  • Price
  • ACRS $1.26
  • TSE $2.52
  • Analyst Decision
  • ACRS Strong Buy
  • TSE
  • Analyst Count
  • ACRS 7
  • TSE 0
  • Target Price
  • ACRS $10.67
  • TSE N/A
  • AVG Volume (30 Days)
  • ACRS 801.8K
  • TSE 284.7K
  • Earning Date
  • ACRS 05-08-2025
  • TSE 05-07-2025
  • Dividend Yield
  • ACRS N/A
  • TSE 1.57%
  • EPS Growth
  • ACRS N/A
  • TSE N/A
  • EPS
  • ACRS N/A
  • TSE N/A
  • Revenue
  • ACRS $17,777,000.00
  • TSE $3,394,000,000.00
  • Revenue This Year
  • ACRS N/A
  • TSE $5.72
  • Revenue Next Year
  • ACRS $425.96
  • TSE $3.80
  • P/E Ratio
  • ACRS N/A
  • TSE N/A
  • Revenue Growth
  • ACRS N/A
  • TSE N/A
  • 52 Week Low
  • ACRS $0.95
  • TSE $1.94
  • 52 Week High
  • ACRS $5.17
  • TSE $7.05
  • Technical
  • Relative Strength Index (RSI)
  • ACRS 43.64
  • TSE 29.80
  • Support Level
  • ACRS $1.20
  • TSE $3.69
  • Resistance Level
  • ACRS $1.46
  • TSE $4.42
  • Average True Range (ATR)
  • ACRS 0.11
  • TSE 0.30
  • MACD
  • ACRS 0.02
  • TSE -0.08
  • Stochastic Oscillator
  • ACRS 41.77
  • TSE 0.52

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About TSE Trinseo PLC

Trinseo PLC is a materials company and manufacturer of latex and plastics products. The company's operating segments include Latex Binders, Americas Styrenics, Engineered Materials, and Polymer Solutions. Maximum revenue is generated from its Polymer Solutions segment, which consists of various polymers, the majority of which are for automotive, building, and construction applications. The product offerings of this segment include ABS, styrene-acrylonitrile, polystyrene, and polycarbonate products, which are marketed through brands like Magnum and Styron. Geographically, the company generates maximum revenue from Europe, followed by the United States, Asia-Pacific, and the Rest of the world.

Share on Social Networks: